HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study
Tóm tắt
An increasing number of people on antiretroviral therapy (ART) in sub-Saharan Africa has led to declines in HIV related morbidity and mortality. However, virologic failure (VF) and acquired drug resistance (ADR) may negatively affect these gains. This study describes the prevalence and correlates of HIV-1 VF and ADR among first-line ART experienced adults at a rural HIV clinic in Coastal Kenya. HIV-infected adults on first-line ART for ≥6 months were cross-sectionally recruited between November 2008 and March 2011. The primary outcome was VF, defined as a one-off plasma viral load of ≥400 copies/ml. The secondary outcome was ADR, defined as the presence of resistance associated mutations. Logistic regression and Fishers exact test were used to describe correlates of VF and ADR respectively. Of the 232 eligible participants on ART over a median duration of 13.9 months, 57 (24.6% [95% CI: 19.2 – 30.6]) had VF. Fifty-five viraemic samples were successfully amplified and sequenced. Of these, 29 (52.7% [95% CI: 38.8 – 66.3]) had at least one ADR, with 25 samples having dual-class resistance mutations. The most prevalent ADR mutations were the M184V (n = 24), K103N/S (n = 14) and Y181C/Y/I/V (n = 8). Twenty-six of the 55 successfully amplified viraemic samples (47.3%) did not have any detectable resistance mutation. Younger age (15–34 vs. ≥35 years: adjusted odd ratios [95% CI], p-value: 0.3 [0.1–0.6], p = 0.002) and unsatisfactory adherence (<95% vs. ≥95%: 3.0 [1.5–6.5], p = 0.003) were strong correlates of VF. Younger age, unsatisfactory adherence and high viral load were also strong correlates of ADR. High levels of VF and ADR were observed in younger patients and those with unsatisfactory adherence. Youth-friendly ART initiatives and strengthened adherence support should be prioritized in this Coastal Kenyan setting. To prevent unnecessary/premature switches, targeted HIV drug resistance testing for patients with confirmed VF should be considered.
Tài liệu tham khảo
UNAIDS : Core slides: Global summary of the AIDS epidemic. 2012, Available at: [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/201207_epi_core_en.pdf]. Accessed 20 Nov 2012, Available at: []. Accessed 20 Nov 2012
UNAIDS : Global AIDS epidemic facts and figures. 2012, Available at: [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/201207_FactSheet_Global_en.pdf]. Accessed 20 Nov 2012, Available at: []. Accessed 20 Nov 2012
NACC and NASCOP : Kenya AIDS Epidemic update. 2012, Available at: [http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_KE_Narrative_Report.pdf]. Accessed 04 April 2013, Available at: []. Accessed 04 April 2013
Bendavid E, Bhattacharya J: The president’s emergency plan for AIDS relief in Africa: an evaluation of outcomes. Ann Intern Med. 2009, 150 (10): 688-695.
Jahn A, Floyd S, Crampin AC: Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet. 2008, 371 (9624): 1603-1611.
UNAIDS : World AIDS Day Report. 2011, Available at: [http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf]. Accessed 20 Nov 2012, Available at: []. Accessed 20 Nov 2012
Gupta RK, Hill A, Sawyer AW: Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009, 9 (7): 409-417.
Keiser O, Tweya H, Boulle A: Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009, 23 (14): 1867-1874.
World Health Organization : Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach -. 2010, Available at: [http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf]. Accessed 20 Nov 2012, rev, Available at: []. Accessed 20 Nov 2012
Badri M, Lawn SD, Wood R: Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis. 2008, 8: 89-
Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD: Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008, 22 (15): 1971-1977.
van Oosterhout JJ, Brown L, Weigel R: Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health. 2009, 14 (8): 856-861.
Barth RE, Tempelman HA, Moraba R, Hoepelman AI: Long-term outcome of an HIV-treatment programme in Rural Africa: viral suppression despite early mortality. AIDS Res Treat. 2011, 2011: 434375-
Kantor R, Diero L, Delong A: Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009, 49 (3): 454-462.
Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM: Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010, 10 (3): 155-166.
Stadeli KM, Richman DD: Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013, 18 (1): 115-123.
National AIDS & STI Control Programme: Kenya National Clinical Manual For ART Providers. Available at: [http://nascop.or.ke/library/ART%20guidelines/Kenya%20clinical%20National%20Manual%20for%20ART%20providers.pdf]. Accessed 20 Nov 2012
Hassan AS, Fielding KL, Thuo NM: Early loss to follow-up of recently diagnosed HIV-infected adults from routine pre-ART care in a rural district hospital in Kenya: a cohort study. Trop Med Int Health. 2012, 17 (1): 82-93.
Goldman JD, Cantrell RA, Mulenga LB: Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses. 2008, 24 (8): 1031-1035.
Weidle PJ, Wamai N, Solberg P: Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet. 2006, 368 (9547): 1587-1594.
Cane P: HIV drug resistance testing. Methods Mol Biol. 2011, 665: 123-132.
Liu TF, Shafer RW: Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006, 42 (11): 1608-1618.
Rhee SY, Gonzales MJ, Kantor R: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003, 31 (1): 298-303.
Kosakovsky Pond SL, Posada D, Stawiski E: An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol. 2009, 5 (11): e1000581-
, : Guidelines for antiretroviral therapy in Kenya. 2011, [Available at: [http://healthservices.uonbi.ac.ke/sites/default/files/centraladmin/healthservices/Kenya%20Treatment%20Guidelines%202011.pdf]. Accessed 04 May 2013, 4, [Available at: []. Accessed 04 May 2013
Stadeli KM, Richman DD: Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013, 18 (1): 115-123.
World Health Organization : HIV Drug Resistance Early Warning Indicators. World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites. 2010, Available at: [http://www2.paho.org/hq/dmdocuments/2010/hivdr-early-warning-indicators—updated-april-2010.pdf]. Accessed 20 Nov 2012, June Update, Available at: []. Accessed 20 Nov 2012
Sigaloff KC, Hamers RL, Menke J: Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis. 2012, 54 (Suppl 4): S294-S299.
El-Khatib Z, Katzenstein D, Marrone G: Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011, 6 (3): e17518-
Nachega JB, Hislop M, Dowdy DW: Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006, 43 (1): 78-84.
Messou E, Chaix ML, Gabillard D: Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Cote d’Ivoire. J Acquir Immune Defic Syndr. 2011, 56 (4): 356-364.
Dowshen N, D’Angelo L: Health care transition for youth living with HIV/AIDS. Pediatrics. 2011, 128 (4): 762-771.
Assoumou L, Descamps D, Yerly S: Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. J Antimicrob Chemother. 2013, 68 (6): 1400-1405.
Nettles RE, Kieffer TL, Kwon P: Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005, 293 (7): 817-829.
Lee PK, Kieffer TL, Siliciano RF, Nettles RE: HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother. 2006, 57 (5): 803-805.
van Sighem A, Zhang S, Reiss P: Immunologic, virologic, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2008, 48 (1): 104-108.
Hamers RL, Wallis CL, Kityo C: HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011, 11 (10): 750-759.
Gupta RK, Jordan MR, Sultan BJ: Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012, 380 (9849): 1250-1258.
Hamers RL, Schuurman R, Sigaloff KC: Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012, 12 (4): 307-317.
Kuritzkes DR, Lalama CM, Ribaudo HJ: Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008, 197 (6): 867-870.
Wittkop L, Gunthard HF, de Wolf F: Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011, 11 (5): 363-371.
Hassan AS, Mwaringa SM, Obonyo CA: Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a Rural HIV clinic in Kenya. AIDS Res Hum Retroviruses. 2013, 29 (1): 129-135.